Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:42:51 EDT Wed 07 Oct 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:JAGX - JAGUAR HEALTH INC - https://jaguar.health
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
JAGX - Q0.25.02·5.193.05.62172.4593378    1,267.875  2.365108:22:59Oct 0615 min RT 2¢

Recent Trades - Last 10 of 378
Time ETExPriceChangeVolume
08:23:06Q5.1264-0.493630
08:22:59Q5.1264-0.49362
08:22:57Q5.12-0.5020
08:22:56Q5.12-0.5062
08:22:51Q5.1288-0.4912130
08:22:51Q5.12-0.50130
08:22:29Q5.118-0.502200
08:22:26Q5.12-0.502
08:22:14Q5.1264-0.493610
08:22:05Q5.13-0.495

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-10-06 09:00U:JAGXNews ReleaseNapo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi
2026-10-02 20:35U:JAGXNews ReleaseJaguar Health Announces a Special Stock Dividend
2026-09-29 04:30U:JAGXNews ReleasePreliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting
2026-09-22 09:05U:JAGXNews ReleaseJaguar Health Receives Fee Waivers from FDA
2026-09-15 09:00U:JAGXNews ReleaseJaguar Health, Inc. Announces Reverse Stock Split
2026-09-10 09:00U:JAGXNews ReleaseAll Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
2026-09-08 09:00U:JAGXNews ReleaseNow Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
2026-09-04 08:30U:JAGXNews ReleaseAdditional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)
2026-08-26 09:00U:JAGXNews ReleaseCommercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
2026-08-19 16:00U:JAGXNews ReleaseJaguar Health Reports Second Quarter 2026 Financials
2026-08-18 09:00U:JAGXNews ReleaseJaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates
2026-08-05 09:00U:JAGXNews ReleaseJaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1
2026-07-28 09:00U:JAGXNews ReleaseJaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog
2026-07-22 09:00U:JAGXNews ReleaseAdditional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)
2026-06-30 09:00U:JAGXNews ReleasePresentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
2026-06-25 09:00U:JAGXNews ReleaseJaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend
2026-06-23 09:00U:JAGXNews ReleaseJaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
2026-06-22 09:00U:JAGXNews ReleaseJaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program
2026-06-18 09:00U:JAGXNews ReleaseMagdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention
2026-06-12 09:00U:JAGXNews ReleaseJaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases